CRISPR Therapeutics logo

CRISPR Therapeutics (CRSP) Q1 2026 Earnings

CRSP·Reported May 4, 2026·Before market open

CRISPR Therapeutics reported Q1 2026 revenue of $1.5M (+68.6% YoY), missed analyst consensus of $6.1M by $4.6M. Diluted EPS came in at $-1.28 (+19.0% YoY), missed the $-1.20 consensus by $0.08.

Revenue
$1.5Mmissed by $4.6M
Consensus: $6.1M
Diluted EPS
$-1.28missed by $0.08
Consensus: $-1.20
SEC

SEC Filings

Earnings release8-K · 0001193125-26-204147
Quarterly report10-Q · 0001193125-26-204188

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about CRISPR Therapeutics's Q1 2026 earnings report.

CRISPR Therapeutics (CRSP) reported Q1 2026 earnings on May 4, 2026 before market open.

CRISPR Therapeutics reported revenue of $1.5M and diluted EPS of $-1.28 for Q1 2026.

Revenue missed the consensus estimate of $6.1M by $4.6M. EPS missed the consensus estimate of $-1.20 by $0.08.

Compared to the same quarter a year prior, revenue grew 68.6% from $865.0K a year earlier and diluted EPS grew 19.0% from $-1.58.

You can read the 8-K earnings release (0001193125-26-204147) and the 10-Q periodic report (0001193125-26-204188) directly on SEC EDGAR. The filing index links above go to sec.gov.